SEC Form 4 · accession 0001203311-16-000084
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Clay B Siegall
Officer — President and CEO · Director
Period of report
Apr 25, 2016
Accepted (ET)
Apr 26, 2016 · 8:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 25, 2016 | M | 800 | $10.20 | A | 556,915 | D | |
| Common StockF2 | Apr 25, 2016 | S | 800 | $40.00 | D | 556,115 | D | |
| Common Stock | holding | — | — | — | 27,945 | I | by Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F3 | $10.20 | Apr 25, 2016 | M | 800 | D | — | May 25, 2017 | Common Stock | 800 | 63,869 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F2Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- F3Shares vested at a rate of 25% on 5/25/08 and monthly thereafter until all the shares were fully vested on 5/25/11.